The FDA’s Center for Drug Evaluation and Research issued its briefing documents arguing for the market withdrawal of Covis Pharma’s Makena. The agency will discuss the drug on Oct. 17-19.
https://www.pharmalive.com/wp-content/uploads/2022/03/Alpine-Cancer-Drug-Hit-with-Partial-Hold-after-Patient-Death-BioSpace-3-7-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-10 11:05:482022-10-10 11:05:48FDA makes argument to withdraw Covis’ Makena from the market
